Celltrion Obtains European Marketing Authorization for Stovoclo and Osenbelt

Three Products Approved in February Alone

Two bone disease treatments from Celltrion have received marketing authorization from the European Commission (EC).

On the 18th, Celltrion announced that it had obtained EC marketing authorization for the biosimilars Stoboclo and Osenbelt of Prolia and Xgeva.

Prolia and Xgeva are drugs approved with the same active ingredient, respectively as treatments for osteoporosis and for the prevention of bone metastasis complications in cancer patients.

Stoboclo has been approved for postmenopausal osteoporosis and bone loss treatment. Osenbelt received marketing authorization for the indications held by the original drugs, including prevention of bone metastasis complications in cancer patients and giant cell tumor of bone.

Including Idenzel, a biosimilar of Eylea approved by the EC last week, Celltrion has obtained approval for three products this month alone. Eylea, developed by Regeneron in the United States, is an ophthalmic treatment for diseases such as wet age-related macular degeneration.

With this authorization, the total global market size of the 11 major products that Celltrion is currently selling or has received approval for reaches approximately 150 trillion KRW.

This content was produced with the assistance of AI translation services.